TipRanks on MSN
Spruce Biosciences Stock Extends 2,900% Rally after FDA Breakthrough Therapy Designation Ignites Investor Frenzy
Spruce Biosciences ($SPRB) is on one of the most dramatic runs in biotech this year. Shares have surged nearly 2,900% over ...
New analysis from Jefferies shows that rare disease and cancer drugs granted the status are especially likely to be approved.
A swathe of top investment banks and funds are piling into emerging market assets on a double-lift in confidence after U.S. President Donald Trump's election defeat and this week's coronavirus vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback